Latin American healthcare provider Auna SAA reported second-quarter revenue of $1.24 billion, exceeding Wall Street’s $1.18 billion estimate by $60 million, or 5.1%, driven by volume growth and higher-margin services across Mexico, Peru and Colombia.
Adjusted earnings per share came in at $0.50, missing the $0.8549 forecast by 41.5%. Adjusted net income totaled PEN 40 million. Full-year 2026 EPS is expected to reach $0.81, according to analysts.
The company’s adjusted EBITDA declined 9% year-over-year on an FX-neutral basis, though management reaffirmed full-year guidance for adjusted EBITDA growth of 10% to 14%, excluding accepted billing penalties in Peru. Net cash from operating activities rose 45% to PEN 441 million in the first half, while free cash flow jumped 181%. The net debt to adjusted EBITDA leverage ratio improved to 3.6x from the prior quarter and is targeting below 3x.
Auna’s stock fell 13.65% in premarket trading on Aug. 19, closing at $4.68, down from a prior close of $5.42. The shares had traded as high as $6.85 and as low as $4.09 over the past 52 weeks.
Regional performance showed Mexico revenue up 4% year-over-year and 5% sequentially, with oncology services revenue rising 110% year-over-year. Peru revenue grew 8%, supported by an 11% increase in Oncosalud revenue and a 6% rise in membership. Colombia revenue advanced 13%, with private payer revenue up 17% and risk-sharing contracts now accounting for 24% of total revenue.
Executive Chairman Suso Zamora highlighted sustained commercial momentum and operational enhancements, while CFO Gisele Remy pointed to strong cash generation as a key highlight of the period.
